{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:10:04Z","timestamp":1790298604403,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Panitumumab has no clinical activity in metastatic RAS wild-type small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC), possibly due to the foregut and midgut derivation of small bowel and ampulla. These results, along with findings from genomic characterization of SBA, suggest that SBA represents a unique intestinal malignancy and treatments should not be habitually extrapolated from colorectal cancer. Further studies evaluating the benefit of targeted therapies exclusively in SBA and AAC are warranted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Given the benefit of epidermal growth factor receptor (EGFR) monoclonal antibodies in colorectal cancer (CRC), we sought to evaluate the efficacy of panitumumab in metastatic RAS wild-type small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-center, open-label, single-arm, Bayesian phase II trial. The primary objective was response rate (RR). Panitumumab was administered at a dose of 6 mg\/kg intravenously (IV) every 14 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nine patients (male\/female 7:2, median age: 61 years [range: 40\u201374], Eastern Cooperative Oncology Group [ECOG] performance status 0\/1: 2\/7) were enrolled from September 2013 to October 2015. One patient had AAC (pancreaticobiliary subtype) and eight patients had SBA (three duodenal, five jejunal\/ileal). Acneiform rash was the most common toxicity. The study was stopped early due to futility with no responses, stable disease (SD) in two patients, and progression of disease (PD) in seven patients. Median progression-free survival (PFS) and overall survival (OS) were 2.4 and 5.7 months, respectively. No patients had extended RAS mutations (exons 2\/3\/4), but two patients had BRAF G469A and one patient had PIK3CA H1074R mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Panitumumab had no clinically meaningful activity in patients with metastatic RAS wild-type SBA and AAC. Our findings may relate to the primarily midgut and foregut derivation of the small bowel and ampulla.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0568","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T16:05:58Z","timestamp":1513699558000},"page":"277-e26","source":"Crossref","is-referenced-by-count":37,"title":["Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater"],"prefix":"10.1093","volume":"23","author":[{"given":"Pat","family":"Gulhati","sequence":"first","affiliation":[{"name":"Hematology\/Oncology Fellowship Program, Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Shroff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Varadhachary","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Applied Mathematics, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Applied Mathematics, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"2021122510332976200_onco12327-bib-0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122510332976200_onco12327-bib-0002","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510332976200_onco12327-bib-0003","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2016.309","article-title":"A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"key":"2021122510332976200_onco12327-bib-0004","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/sim.4780140404","article-title":"Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes","volume":"14","author":"Thall","year":"1995","journal-title":"Stat Med"},{"key":"2021122510332976200_onco12327-bib-0005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L","article-title":"Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials","volume":"17","author":"Thall","year":"1998","journal-title":"Stat Med"},{"key":"2021122510332976200_onco12327-bib-0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2021122510332976200_onco12327-bib-0007","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122510332976200_onco12327-bib-0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1634\/theoncologist.10-2-132","article-title":"Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma","volume":"10","author":"Gibson","year":"2005","journal-title":"The Oncologist"},{"issue":"suppl 4","key":"2021122510332976200_onco12327-bib-0009","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/jco.2012.30.4_suppl.314","article-title":"Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial","volume":"30","author":"McWilliams","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122510332976200_onco12327-bib-0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs"},{"key":"2021122510332976200_onco12327-bib-0011","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cncr.30445","article-title":"Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study","volume":"123","author":"Gulhati","year":"2017","journal-title":"Cancer"},{"key":"2021122510332976200_onco12327-bib-0012","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nrd2204","article-title":"Panitumumab","volume":"5","author":"Saltz","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2021122510332976200_onco12327-bib-0013","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0344-0338(11)80652-7","article-title":"Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours","volume":"191","author":"Lee","year":"1995","journal-title":"Pathol Res Pract"},{"key":"2021122510332976200_onco12327-bib-0014","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6605449","article-title":"Immunophenotype and molecular characterization of adenocarcinoma of the small intestine","volume":"102","author":"Overman","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122510332976200_onco12327-bib-0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrclinonc.2013.132","article-title":"Small bowel adenocarcinomas\u2013Existing evidence and evolving paradigms","volume":"10","author":"Raghav","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122510332976200_onco12327-bib-0016","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6605899","article-title":"Reply: Cetuximab in small bowel adenocarcinoma: A new friend?","volume":"103","author":"Overman","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122510332976200_onco12327-bib-0017","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000332043","article-title":"Small bowel adenocarcinoma presenting with refractory iron deficiency anemia \u2013 Case report and review of literature","volume":"4","author":"Poddar","journal-title":"Case Rep Oncol 2011;"},{"key":"2021122510332976200_onco12327-bib-0018","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.bjc.6605898","article-title":"Cetuximab in small bowel adenocarcinoma: A new friend?","volume":"103","author":"Santini","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122510332976200_onco12327-bib-0019","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomized phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"2021122510332976200_onco12327-bib-0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122510332976200_onco12327-bib-0021","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122510332976200_onco12327-bib-0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic profiling of small-bowel adenocarcinoma","author":"Schrock","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122510332976200_onco12327-bib-0023","first-page":"22","article-title":"Right-sided vs left-sided colorectal cancer","volume":"15","author":"Venook","year":"2017","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/277\/41915517\/oncolo_23_3_277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/277\/41915517\/oncolo_23_3_277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:33:59Z","timestamp":1640428439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/3\/277\/6439303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,12,19]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0568","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3,1]]},"published":{"date-parts":[[2017,12,19]]}}}